Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Morning versus evening dosing of tofacitinib in inflammatory arthritis
ISRCTN68663074Phase 4Recruiting
- Sponsor
- Erasmus MC
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of tofacitinib in rheumatoid arthritis (RA) and psoriatic arthritis (PsA) (2 arms), sponsored by Erasmus MC. Primary endpoint: RAPID3 disease activity at 3 months. Started Mar 2022; status: recruiting.
02
Drugs
03
Conditions
rheumatoid arthritis (RA)psoriatic arthritis (PsA)
Beyond the preview
Go deeper on ISRCTN68663074.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN68663074.